Nykode Therapeutics Full Year 2024 Earnings: Beats Expectations

Nykode Therapeutics (OB:NYKD) Full Year 2024 Results

Key Financial Results

• Net loss: US$38.8m (loss widened by 10% from FY 2023).
• US$0.12 loss per share (further deteriorated from US$0.12 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nykode Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 172%. Earnings per share (EPS) also surpassed analyst estimates by 23%.

Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Norway.

Performance of the Norwegian Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Nykode Therapeutics is showing 3 warning signs in our investment analysis and 1 of those is a bit concerning...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.